tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MRKR Stock Latest News

Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
RatingsValidating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
9d ago
MRKR
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
PremiumThe Fly
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
9d ago
MRKR
Marker Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Marker Therapeutics initiated with a Buy at H.C. Wainwright
1M ago
MRKR
Marker Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Marker Therapeutics Reports Q3 2025 Financial Results
2M ago
MRKR
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
PremiumCompany Announcements
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
2M ago
MRKR
Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year
PremiumThe FlyMarker Therapeutics reports Q3 EPS (12c) vs (26c) last year
2M ago
MRKR
Marker Therapeutics Strengthens Board with New Appointment
Premium
Company Announcements
Marker Therapeutics Strengthens Board with New Appointment
2M ago
MRKR
Marker Therapeutics appoints Penkus Corzo to board of directors
Premium
The Fly
Marker Therapeutics appoints Penkus Corzo to board of directors
2M ago
MRKR
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
PremiumCompany Announcements
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
3M ago
MRKR
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
PremiumCompany Announcements
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
3M ago
MRKR
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
PremiumCompany Announcements
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
3M ago
MRKR
Marker Therapeutics announces first patient treated in off-the-shelf program
PremiumThe Fly
Marker Therapeutics announces first patient treated in off-the-shelf program
3M ago
MRKR
Marker Therapeutics Reports Promising Phase 1 Study Results
PremiumCompany AnnouncementsMarker Therapeutics Reports Promising Phase 1 Study Results
5M ago
8K
MRKR
Marker Therapeutics provides update on observations from Phase 1 APOLLO study
Premium
The Fly
Marker Therapeutics provides update on observations from Phase 1 APOLLO study
5M ago
MRKR
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline
Premium
Company Announcements
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline
5M ago
MRKR
Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics
PremiumRatings
Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics
5M ago
MRKR
Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics
PremiumRatings
Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics
7M ago
MRKR
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing
PremiumCompany Announcements
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing
7M ago
8K
MRKR
Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601
PremiumThe Fly
Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601
7M ago
MRKR
Marker Therapeutics Concludes Annual Stockholders Meeting
PremiumCompany AnnouncementsMarker Therapeutics Concludes Annual Stockholders Meeting
7M ago
8K
MRKR
Marker Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Marker Therapeutics Reports Q1 2025 Financial Results
7M ago
MRKR
Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
Premium
Ratings
Buy Rating Maintained for Marker Therapeutics Due to Promising MT-601 Developments and APOLLO Study Progress
8M ago
MRKR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >